Based on our previous findings that the prognosis of patients with different invasive BC subtypes is related to the differential expression of ten neurogenes (NTN1, HRH1, NRP2, STX1A, GRID1, NGFR, CNTFR, SLC17A7, ADORA1, APP) [16], we evaluated the expression of these genes and other related molecules, as well as some of their receptors/coreceptors and ligands (Supplementary Table 1), in our panel of BC cell lines. This evidence concerns the gene HRH1 and breast cancer.